Occlutech
Growth · Switzerland · 2021
Company
Occlutech AG is an international medical technology company specializing in minimally invasive implants for the treatment of structural heart diseases.
Founded in 2003, the company develops and markets occlusion devices, including those used to treat heart defects such as patent foramen ovale (PFO) and atrial septal defect (ASD). Occlutech has positioned itself as a technology leader in a highly regulated, globally growing niche market and distributes its products in numerous countries worldwide.
Managing Directors: Tor Peters, Dr. Luis Martin-Parras
Reason for the Investment
In December 2021, COI Partners invested in Occlutech as part of a Series C funding round.
At the time of the investment, the company was in a critical growth phase: Clinical trials for entry into the U.S. market were underway, the product pipeline was clearly defined, and the international distribution network was already established in over 80 countries. For COI Partners, Occlutech represented a rare combination of proven technology, clearly identifiable growth potential, and a strong regulatory track record.
Key Figures
0
Year Founded
0
Year of Participation
Growth
Transaction Type
Contact Person at COI
Our Deal Captain, Julian Kohl, is in charge of Occlutech:
“Structural heart diseases affect millions of people worldwide, and minimally invasive treatment options are the clinical standard of the future. Occlutech is a technological leader in this market and has a clear commitment to quality that is recognized internationally. This is the kind of company we, as investors, are built for.”
"As investors, we see entrepreneurship as a driving force.
By this we mean the mindset, the vision, and the determination to create something."
Investments
Learn more about our portfolio.
Here you will find an overview focusing on our active portfolio companies and the background information on our investments. We are proud to have made more than 100 initial and follow-on investments over the past 25 years.
